Loading stock data…
$19.43+1.55 (+8.67%)
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Legend Biotech Corporation in the Healthcare sector is trading at $19.43 with a market capitalization of $3.8B. Wall Street consensus targets $45.73 (13 analysts), implying a +135.4% move over the next 12 months. The stock is currently near its 52-week low of $16.24, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $387.50M↑ | $305.10M↓ | $306.38M↑ | $272.33M↑ | $255.10M |
| Gross Profit | $250.10M↑ | $129.20M↓ | $182.92M↑ | $157.02M | $157.10M |
| Operating Income | $57.70M↑ | -$49.80M↓ | -$20.60M↑ | -$43.45M↓ | -$21.90M |
| Net Income | $33.20M↑ | -$54.30M↓ | -$30.82M↑ | -$39.69M↑ | -$125.40M |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. ...